Comparing TuHURA Biosciences (HURA) & Its Rivals

TuHURA Biosciences (NASDAQ:HURA) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its peers? We will compare TuHURA Biosciences to similar businesses based on the strength of its valuation, analyst recommendations, earnings, dividends, risk, profitability and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for TuHURA Biosciences and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1	0	3	2	3.00
TuHURA Biosciences Competitors	5770	12187	37606	1167	2.60

TuHURA Biosciences presently has a consensus target price of $10.33, indicating a potential upside of 493.87%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 55.09%. Given TuHURA Biosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe TuHURA Biosciences is more favorable than its peers.

Insider & Institutional Ownership

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares TuHURA Biosciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-248.79%	-150.83%
TuHURA Biosciences Competitors	-1,425.99%	-589.65%	-28.81%

Valuation and Earnings

This table compares TuHURA Biosciences and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
TuHURA Biosciences	N/A	-$21.68 million	-3.48
TuHURA Biosciences Competitors	$959.03 million	-$45.26 million	12.33

TuHURA Biosciences’ peers have higher revenue, but lower earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

About TuHURA Biosciences

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.